India / 200% Pharma Sector Budget Boost; 3x Industry Growth in Next Decade; Pfizer Vaccine Rebuffed
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in…
india
India / Global Implications of COVID Crisis; April Market Rebound; Roche/Regeneron Approval; Lilly baricitinib Partnerships
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis…
Mexico / Indian Investment to Bolster Domestic Supply Chain post-COVID
COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in…
India / Pharma Market to Grow by 12-14% Up to 2023
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands…
In Conversation
Interview: RS Raghav – Managing Director, Oaknet Healthcare, India
RS Raghav, founder and managing director of Oaknet Healthcare, documents the key fundamentals that have enabled Oaknet to proudly become a Top 100 player in the competitive Indian market within only three years of existence. Looking forward, he also documents the importance of in-licensing partnerships, digitalization, and the company’s expertise in identifying unmet market needs to further propel its growth…
APAC / Generic Penetration by Country
Generics penetration in the Asia-Pacific region by country for 2018. A full 90.3 percent of all medicines dispensed…
Related Report
Digital Health: India
An insight into digital health in Indian Pharma. Prepared in association with Nishith Desai & Associates, a…
India: Good Endings, Good Beginnings
What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take…
MNCs’ Healthcare Access Initiatives in India
With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to…
India / Six Companies at the Forefront of COVID-19 Vaccine Development
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with…
US Generics / Biocon’s Recipe for Success in a Competitive Market
Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of…
China: Indian Pharma Firms Incoming
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports…
Quality Compliance in Indian Pharma: The Learning Curve
One issue grinding the gears of the Indian pharmaceutical industry over recent years has been quality compliance.…
India / Global Implications of COVID Crisis; April Market Rebound; Roche/Regeneron Approval; Lilly baricitinib Partnerships
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April,…
Mexico / Indian Investment to Bolster Domestic Supply Chain post-COVID
COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in…
LatAm / What Can Brazil’s Pharma Industry Learn from India?
The editorial team at Panorama Farmaceutico explain why coordinated action is needed within Brazilian pharma to…
India: An Emerging Knowledge Superpower
“India, as a manufacturing hub, offers safe, effective, quality medicines, at the very best prices. Now, we…
LatAm / Big Indian Investment; Argentina's COVID-19 Woes; Cannabis ‘Green Rush’ in Mexico
The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma…
The COVID-19 Vaccine Rush / Nationalism, Access & IP Issues
The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding…
Meeting US FDA Standards Across the Board in India
In a context where even well-established, multi-billion-dollar domestic companies have received warning letters…
Geopolitics / Three Key Issues for Pharma: Protests, Pricing & India’s Modicare
This month, Aditya Bhattacharji takes stock of three political issues that are dominating Eurasia Group’s…
Indian Contract Research Industry Set for Rapid Growth
The global pharmaceutical outsourcing market was estimated to be USD 115.7 billion in 2016, of which 49 percent is…
Coronavirus / Indian Pharma Supply Chain Hit by Covid-19 Outbreak
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions…
Geopolitics / Three More Key Issues for Pharma: Regulatory Assertiveness, Climate Change & India’s Health Policy Renaissance
Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be…
India: Creating An Innovative Healthcare Ecosystem
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based…
Supply Chain / Indian Pharma Manufacturing: Back in Business
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and…
India / 200% Pharma Sector Budget Boost; 3x Industry Growth in Next Decade; Pfizer Vaccine Rebuffed
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in…
Africa: The Launchpad for Indian Pharma
Although most industry observers expect that Indian pharma exports to the US will pick up again in the coming…
Indian Biosimilars: Going Global
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven…
Indian Generics in the USA / Destined for More Success?
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic…
10 Pharma Leaders to Know in India
Indian pharma companies provide affordable generic drugs to patients in almost all countries across the globe,…
Gender Diversity in Indian Pharma
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the…
Indian Pharma Manufacturing: Serving the World
Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign…
India: Still a Land of Opportunity for MNCs
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India…